title: Biotech comes to its 'antisenses' after hard-won drug approval.
authors: Kevin
authors: K
authors: Jiang
mesh_terms: D001053:Apolipoproteins / Q000096:biosynthesis; D017277:Drug Approval; D016503:Drug Delivery Systems; D004345:Drug Industry; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D020319:Oligodeoxyribonucleotides, Antisense / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009841:Oligonucleotides / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013873:Thionucleotides / Q000627:therapeutic use
chemical_list: D001053:Apolipoproteins; D020319:Oligodeoxyribonucleotides, Antisense; D009841:Oligonucleotides; D013873:Thionucleotides; C408162:oblimersen; C524142:mipomersen